RNXT NASDAQ
RenovoRx, Inc.
1W: -4.8%
1M: -37.3%
3M: +66.7%
YTD: +89.2%
1Y: +17.9%
3Y: +21.5%
5Y: -77.5%
$1.58
+0.03 (+1.94%)
Weekly Expected Move ±12.0%
$1
$1
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (53)
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
RenovoRx, Inc. (NASDAQ:RNXT) Stock Short Interest Jumps 55.7%
These low-priced stocks are flashing overbought signals
The best Quant-rated stocks trading below $10 right now
RenovoRx FY2026 EPS Raised by Ascendiant Capital Markets
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
RenovoRx (RNXT) Q2 2026 Earnings Call Transcript
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
RenovoRx (RNXT) Q1 2026 Earnings Transcript
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
HC Wainwright Issues Negative Forecast for RenovoRx Earnings
FY2027 EPS Estimates for RenovoRx Lowered by HC Wainwright
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
RenovoRx GAAP EPS of -$0.32 in-line, revenue of $1.12M misses by $0.18M
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
Earnings Scheduled For March 30, 2026
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
RenovoRx announces $10 million private placement
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Down 20.6% in February
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
RenovoRx Establishes RenovoCath® Medical Advisory Board
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th